Freidin Aaron sold $672K of GRAL

Grail (GRAL) stock rose after FDA advisors endorsed its cancer-detecting blood test. Analyst Kyle Mikson expects FDA approval but notes potential label nuances. The Galleri test is marketed for multi-cancer early detection.

Grail Inc (GRAL) shares fell 3.23% to $105.01 after a week of gains, following a mixed FDA panel vote on its Galleri test. The panel found it safe and beneficial but had a narrow vote on effectiveness. Analysts are divided on its valuation, with targets ranging from $80 to $118. The company reported a loss in its last quarter and faces risks related to financing and cash burn. Technical indicators suggest overbought conditions.

Grail Inc's stock surged 11.3% to $120.81 after an FDA panel voted that the benefits of its Galleri multi-cancer detection test outweigh risks for adults 50+. The panel also unanimously supported its safety. Analysts raised price targets and maintained positive ratings. The FDA's final decision is pending, with some uncertainty remaining. The move is company-specific, with broader markets down.

GRAIL Inc.'s (GRAL) Galleri multi-cancer early detection test received a favorable vote from an FDA panel, advancing its approval process. The test aims to detect cancer early by analyzing DNA fragments in blood. The panel unanimously supported its safety, with mixed votes on effectiveness and benefit-risk. GRAIL claims Galleri detects 4-7x more cancers than standard screening. The FDA's final decision is expected soon. GRAL stock was halted at $108.52 ahead of the vote.

An FDA panel backed GRAIL's Galleri multi-cancer blood test for safety and benefits over risks, but split on effectiveness. The test detected about 35% of cancers in trials. FDA approval could expand marketing and insurance coverage. GRAL stock rallied 34% on Monday and is up 27% year-to-date.

Grail (GRAL) received FDA panel backing for its Galleri blood test to detect cancer, according to Bloomberg. The panel voted 6-4 on effectiveness and agreed on safety. Baird raised its price target to $118 from $86, while Mizuho noted FDA briefing documents were favorable to approval. Analysts maintain a hold rating, citing priced-in regulatory upside.